Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vistin Pharma ASA ( (DE:VP4) ) just unveiled an update.
Vistin Pharma ASA announced that it will release its fourth quarter and preliminary 2024 results on February 13, 2025. The company will host a conference call for shareholders and interested parties on the same day, featuring a management discussion and a Q&A session. This announcement highlights Vistin Pharma’s commitment to transparency and engagement with stakeholders, which may impact its market positioning and investor relations positively.
More about Vistin Pharma ASA
Vistin Pharma is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride, an active pharmaceutical ingredient (API). The company offers Metformin as Direct Compressible lubricated granules and is a key supplier to leading pharmaceutical companies in Europe. Headquartered in Oslo, Vistin Pharma operates a dedicated manufacturing facility in Kragerø.
YTD Price Performance: 2.00%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €89.32M
Find detailed analytics on VP4 stock on TipRanks’ Stock Analysis page.